Thyrocare Technologies Limited has informed the Exchange regarding Re-appointment of Mr. Rahul Franklin Guha as Managing Director & CEO of the company w.e.f. May 04, 2027.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Thyrocare's Board approved multiple items at its May 7, 2026 meeting. Key decisions include recommending a final dividend of Rs. 7 per share for FY26 (bringing total dividend to Rs. 9.33 per share post-bonus), appointing Price Waterhouse Chartered Accountants LLP as the new statutory auditor for a 5-year term replacing M S K A & Associates, and re-appointing Mr. Rahul Franklin Guha as Chairman, Managing Director & CEO for another 5 years starting May 4, 2027. The Board also appointed two new Non-Executive, Non-Independent Directors — Mr. Uday Patel Kadam and Mr. Gaurav Verma, both from API Holdings — effective May 8, 2026. Two existing Non-Executive Directors, Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah, resigned citing pre-occupation and other commitments. Additionally, the Board approved investing up to Rs. 5.5 crore in Think Health Diagnostics Private Limited, a wholly-owned subsidiary, and proposed amendments to the MOA aligning it with the Companies Act 2013 and broadening the objects clause to cover a wider range of healthcare and diagnostics activities.
The resignation of two directors on the same day may raise minor governance concerns, though both cited personal commitments and the company confirmed no material disputes. The CEO's reappointment and new director appointments from API Holdings signal continued alignment with the parent group. The MOA amendment hints at potential expansion beyond diagnostics into broader healthcare services.